Correction: Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial
- PMID: 41081802
- DOI: 10.1007/s00134-025-08146-y
Correction: Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial
Erratum for
-
Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial.Intensive Care Med. 2025 Sep;51(9):1615-1627. doi: 10.1007/s00134-025-08064-z. Epub 2025 Aug 6. Intensive Care Med. 2025. PMID: 40768068 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
